Blog
RSS FeedPosted by Michael Wonder on 06 May 2021
The difference between an interchangeable biosimilar and one that isn't
5 May 2021 - Permitting automatic substitution of biosimilars for originator brand biologics at the pharmacy counter is often talked about ...
Posted by Michael Wonder on 29 Apr 2021
Toothful or toothless? Biden's biosimilar bills under the microscope
28 April 2021 - How much muscle did Congress invest in a pair of bills recently signed by President Biden? ...
Posted by Michael Wonder on 29 Apr 2021
Valeo Pharma’s Redesca and Redesca HP to be covered under the Ontario Public Drug Benefit Program
28 April 2021 - Additional provincial coverage expected to follow. ...
Posted by Michael Wonder on 22 Apr 2021
New Brunswick becomes third province in Canada to implement biosimilar switching policy
21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning ...
Posted by Michael Wonder on 30 Mar 2021
Samsung Bioepis continues global market expansion with launch of Hadlima in Australia and Canada in partnership with Merck
29 March 2021 - Samsung Bioepis’ adalimumab is now available in three markets: Europe, Canada and Australia. ...
Posted by Michael Wonder on 16 Mar 2021
Once again, the viability of the U.S. biosimilar market is thrown into question
15 March 2021 - Despite periodic reports that biosimilars have finally arrived and will save the U.S. health care system ...
Posted by Michael Wonder on 09 Mar 2021
Request for proposals - supply of adalimumab
9 March 2021 - PHARMAC invites proposals for the supply of adalimumab in New Zealand. ...
Posted by Michael Wonder on 18 Feb 2021
Viatris launches Hulio (adalimumab biosimilar) in Canada
18 February 2021 - Viatris announced today that Health Canada has approved Hulio, and product is now available in Canada. ...
Posted by Michael Wonder on 18 Feb 2021
Coherus BLA filing for adalimumab biosimilar candidate accepted by FDA for review
17 February 2021 - Coherus BioSciences announced that the United States FDA has accepted for review the 351(k) biologics license application ...
Posted by Michael Wonder on 18 Feb 2021
Fresenius Kabi Canada launches Idacio (adalimumab injection) a biosimilar to Humira (adalimumab) for the treatment of multiple chronic inflammatory conditions
18 February 2021 - Biosimilars offer patients access to affordable, meaningful medicines ...
Posted by Michael Wonder on 17 Feb 2021
Sandoz Canada completes its fifth biosimilar launch with new biosimilar Hyrimoz (adalimumab)
16 February 2021 - Hyrimoz for use in nine indications covered by the reference medicine in the fields of rheumatology, gastro-enterology ...
Posted by Michael Wonder on 16 Feb 2021
Celltrion Healthcare receives European Commission approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, Yuflyma (CT-P17)
15 February 2021 - Yuflyma is approved in all intended indications for the treatment of multiple chronic inflammatory diseases. ...
Posted by Michael Wonder on 14 Feb 2021
Biosimilars: is interchangeability the proof of the pudding?
15 February 2021 - While apparently non‐inferior to originator biologics, other factors need to be considered before switching ...
Posted by Michael Wonder on 02 Feb 2021
Celltrion Healthcare receives Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, Remsima SC, for the treatment of people with rheumatoid arthritis
1 February 2021 - This novel formulation provides an alternative administration option for Canadian physicians and their patients. ...
Posted by Michael Wonder on 28 Jan 2021
Bio-Thera Solutions announces FDA accepts biologics license application for BAT1706, a proposed biosimilar to Avastin
28 January 2021 - Bio-Thera Solutions today announced that the U.S. FDA has accepted its biologics license application for BAT1706, a ...